



SAFETY DATA SHEET

Revision date: 01-Apr-2015

Version: 2.0

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Conjugated Estrogens Vaginal Cream (US)

Trade Name: PREMARIN

Chemical Family: Steroid

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for hormone replacement therapy

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Signal Word: Not required

Hazard Statements: Non-hazardous in accordance with international standards for workplace safety.

Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 2 of 11
Version: 2.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Cetyl alcohol	36653-82-4	253-149-0	Not Listed	Not Listed	*
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*
Glyceryl monostearate	31566-31-1	250-705-4	Not Listed	Not Listed	*
Benzyl Alcohol	100-51-6	202-859-9	Xn; R20/22	Acute Tox.4 (H302) Acute Tox.4 (H332)	*
Glycerin, USP	56-81-5	200-289-5	Not Listed	Not Listed	*
Conjugated estrogens	12126-59-9	235-199-5	Carc.Cat.1;R45 Repr.Cat.1;R60 Repr.Cat.1;R61	Carc. 1A,H350; Repr. 1A,H360FD	0.0625

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
White wax	8006-40-4	Not Listed	Not Listed	Not Listed	*
Water, purified	7732-18-5	231-791-2	Not Listed	Not Listed	*
Methyl stearate	112-61-8	203-990-4	Not Listed	Not Listed	*
Mineral oil, white	8042-47-5	232-455-8	Not Listed	Not Listed	*
Cetyl stearate	1190-63-2	214-724-1	Not Listed	Not Listed	*
Fatty acids, C16-18, esters with propylene glycol	91031-35-5	292-936-3	Not Listed	Not Listed	*

Additional Information:

* Proprietary
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
 In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:	Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash off immediately with soap and plenty of water. If irritation occurs or persists, get medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure:	None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:	None
----------------------------	------

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 3 of 11
Version: 2.0

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing mist or aerosols. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Cetyl alcohol

Germany - TRGS 900 - TWAs	20 ppm
	200 mg/m ³

Sodium lauryl sulfate

Pfizer OEL TWA-8 Hr:	0.3 mg/m ³
----------------------	-----------------------

Glyceryl monostearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 4 of 11
Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Sweden OEL - TWAs	5 mg/m ³
Benzyl Alcohol	
Bulgaria OEL - TWA	5.0 mg/m ³
Czech Republic OEL - TWA	40 mg/m ³
Finland OEL - TWA	10 ppm
	45 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Poland OEL - TWA	240 mg/m ³
Mineral oil, white	
ACGIH Threshold Limit Value (TWA)	5 mg/m ³
ACGIH Threshold Limit Value (STEL)	10 mg/m ³ (oil mist)
Glycerin, USP	
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Czech Republic OEL - TWA	10 mg/m ³
Estonia OEL - TWA	10 mg/m ³
Finland OEL - TWA	20 mg/m ³
France OEL - TWA	10 mg/m ³
Germany (DFG) - MAK	50 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	50 mg/m ³
Conjugated estrogens	
Pfizer OEL TWA-8 Hr:	0.15µg/m ³
Cetyl stearate	
ACGIH Threshold Limit Value (TWA)	10 mg/m ³

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 5 of 11
Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Cream	Color:	White
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

White wax

No data available

Benzyl Alcohol

No data available

Cetyl alcohol

No data available

Glycerin, USP

No data available

Sodium lauryl sulfate

No data available

Glyceryl monostearate

No data available

Conjugated estrogens

No data available

Water, purified

No data available

Cetyl stearate

No data available

Mineral oil, white

No data available

Fatty acids, C16-18, esters with propylene glycol

No data available

Decomposition Temperature (°C):	No data available.
--	--------------------

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 6 of 11
Version: 2.0

10. STABILITY AND REACTIVITY

Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Short Term:

May cause eye and skin irritation (based on components)

Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).

Known Clinical Effects:

Clinical use of this drug has caused menstrual irregularities, lack of menstrual periods (amenorrhea), changes in cervical erosion and secretion, breast enlargement, breast pain, breast development in males (gynecomastia), nausea, vomiting, abdominal cramping, weight changes, fluid retention, changes in sexual desire (libido), loss of hair, mental depression.

Acute Toxicity: (Species, Route, End Point, Dose)

Benzyl Alcohol

Rat	Oral	LD50	1230 mg/kg
Rat	Para-periosteal	LD50	53mg/kg
Rat	Inhalation	LC50	>4.178mg/L

Cetyl alcohol

Rat	Oral	LD50	5000 mg/kg
Rabbit	Dermal	LD50	> 2,600 mg/kg
Mouse	Oral	LD50	3200 mg/kg

Glycerin, USP

Mouse	Oral	LD50	4090 mg/kg
Rat	Oral	LD50	12.6 g/kg
Rabbit	Dermal	LD50	> 10 g/kg
Rat	Inhalation	LC50 1hr	> 570 mg/m ³
Rat	Dermal	LD 50	> 21.9 g/kg

Sodium lauryl sulfate

Rat	Oral	LD50	1288 mg/kg
-----	------	------	------------

Glyceryl monostearate

Mouse	IP	LD50	200 mg/kg
-------	----	------	-----------

Conjugated estrogens

Rat	IP	LD50	325 mg/kg
-----	----	------	-----------

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 7 of 11
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Mouse IV LD50 1740mg/kg
Rat Oral LD50 > 5000mg/kg

Mineral oil, white

Rat Oral LD50 > 5000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Benzyl Alcohol

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Minimal
Skin Irritation Guinea Pig Moderate

Glycerin, USP

Eye Irritation Rabbit Mild

Sodium lauryl sulfate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild Moderate
Skin Sensitization - GPMT Guinea Pig Negative
Skin Sensitization - LLNA Mouse Negative

Conjugated estrogens

Eye Irritation Rabbit Severe

Mineral oil, white

Skin Irritation Rabbit Slight
Eye Irritation Rabbit Slight

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Conjugated estrogens

Embryo / Fetal Development Rat Subcutaneous 7 mg/kg/day LOAEL Embryotoxicity, Fetotoxicity

Sodium lauryl sulfate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status: See below

Conjugated estrogens

IARC: Group 1
NTP: Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 8 of 11
Version: 2.0

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Benzyl Alcohol

Pimephales promelas (Fathead Minnow) EPA LC50 96 Hours 460 mg/L
Daphnia magna (Water Flea) OECD EC50 48 Hours 230 mg/L
Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 Hours 500 mg/L

Glycerin, USP

Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L
Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Sodium lauryl sulfate

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 3.6 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Benzyl Alcohol

Daphnia magna (Water Flea) OECD 21 Day(s) EC50 66 mg/L Reproduction

Persistence and Degradability: No data available

Benzyl Alcohol

OECD Activated sludge Ready 92% After 14 Day(s) Ready

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 9 of 11
Version: 2.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Cetyl alcohol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	253-149-0

White wax

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Sodium lauryl sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1

Water, purified

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Methyl stearate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 10 of 11
Version: 2.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	203-990-4
Glyceryl monostearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	250-705-4
Benzyl Alcohol	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-859-9
Mineral oil, white	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-455-8
Glycerin, USP	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex V - Exemptions from the obligations of Register:	Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern
EU EINECS/ELINCS List	200-289-5
Conjugated estrogens	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen, initial date 2/27/87; developmental. initial date 4/1/90
EU EINECS/ELINCS List	235-199-5
Cetyl stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	214-724-1

SAFETY DATA SHEET

Material Name: Conjugated Estrogens Vaginal Cream (US)
Revision date: 01-Apr-2015

Page 11 of 11
Version: 2.0

15. REGULATORY INFORMATION

Fatty acids, C16-18, esters with propylene glycol

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

EU EINECS/ELINCS List

292-936-3

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.1A; H350 - May cause cancer

Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled

Carcinogenic: Category 1

Toxic to reproduction: Category 1

Xn - Harmful

R45 - May cause cancer.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

R22 - Harmful if swallowed.

R20/22 - Harmful by inhalation and if swallowed.

Data Sources:

Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision:

Updated Section 3 - Composition / Information on Ingredients. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date:

01-Apr-2015

Prepared by:

Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet